Sutro biopharma

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways, sutro biopharma. Many thanks to sutro biopharma Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link.

Key events shows relevant news articles on days with large price movements. Gossamer Bio Inc. GOSS 4. Kezar Life Sciences Inc. KZR 0.

Sutro biopharma

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA. Sutro was named one of Fierce Biotech's Fierce 15 in Contents move to sidebar hide. Article Talk. Read Edit View history. Tools Tools. Download as PDF Printable version.

Net income. Total assets The total amount of assets owned by a company. Skip to main content.

Skip to main content. Sutro Biopharma, Inc. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. Vaxcyte, Inc. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the third quarter of , its recent business highlights, and a preview of select anticipated milestones. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the second quarter of , its recent business highlights, and a preview of select anticipated milestones.

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link. Dedicated to our Patients and Changing the Future of Oncology. Learn More. Sutro Biopharma, Inc. Our Technology.

Sutro biopharma

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA. Sutro was named one of Fierce Biotech's Fierce 15 in Contents move to sidebar hide.

Ahsoka tano porn comics

Stock Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned. Please help improve this article by adding citations to reliable sources. Operating expense. Kezar Life Sciences Inc. KZR 0. PMC Net change in cash. Authority control databases ISNI. The average number of shares traded each day over the past 30 days. Previous close.

.

Learn more. Price to book. Homeless Prenatal Program. Cash from operations. Net change in cash The amount by which a company's cash balance increases or decreases in an accounting period. Contents move to sidebar hide. Authority control databases ISNI. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Earnings per share. Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances. Cash from investing Net cash used or generated in investing activities such as purchasing assets. Allakos Inc. Stock Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned. Endpoints News.